Prophylactic treatment of known ifosfamide-induced encephalopathy for chemotherapy with high-dose ifosfamide?

被引:17
|
作者
Kasper, B [1 ]
Harter, C [1 ]
Meissner, J [1 ]
Bellos, F [1 ]
Krasniqi, F [1 ]
Ho, AD [1 ]
Egerer, G [1 ]
机构
[1] Univ Heidelberg, Dept Internal Med 5, D-69115 Heidelberg, Germany
关键词
ifosfamide-induced encephalopathy; Ewing sarcoma; high-dose chemotherapy (HDCT); peripheral blood stem cell transplantation (PBSCT);
D O I
10.1007/s00520-003-0573-2
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We report about a case of advanced Ewing sarcoma in a 30-year-old woman. Initial treatment was started according to the Euro-Ewing 99 protocol. During the initial therapy, an ifosfamide-induced encephalopathy occurred as status epilepticus. Because of cerebral toxicity, the following chemotherapies went without ifosfamide. During final radiotherapy multiple lung metastasis were diagnosed. After two cycles of chemotherapy with cyclophosphamide and topotecan (no response), left thoracotomy, and palliative pneumectomy, the patient was transferred to our ward for further treatment. Undergoing two cycles of chemotherapy with ifosfamide 4 g/m(2) intravenously for 3 consecutive days followed by high-dose chemotherapy (HDCT) according to the ICE-regimen ( ifosfamide 2 g/m(2), carboplatin 200 mg/m(2), and etoposide 2 x 100 mg/m(2) intravenously for 6 consecutive days), and peripheral blood stem cell transplantation (PBSCT), complete remission was achieved. Under preventive therapy with methylene blue, thiamin, and glucose 5% infusions, no encephalopathy occurred.
引用
收藏
页码:205 / 207
页数:3
相关论文
共 50 条
  • [41] Reversible ifosfamide-induced encephalopathy with bursts of triphasic waves responsive to levetiracetam
    Zubko, Luis Eduardo Borges de Macedo
    Brandao, Lucas Altoe
    Disserol, Caio Cesar Diniz
    Nascimento, Igor Ibrahim
    de Paola, Luciano
    ARQUIVOS DE NEURO-PSIQUIATRIA, 2024, 82 (11) : 2 - 3
  • [42] Differences in ifosfamide-induced encephalopathy after use of two different formulations
    Beau-Salinas, F.
    Bousquet-Plichon, C.
    De la Bretonniere, M. Ertault
    Jourdain, A.
    Andre, V.
    Vrignaud, L.
    Jonville-Bera, A. P.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2016, 30 : 31 - 31
  • [43] Ifosfamide-induced nephrotoxicity : Mechanism and prevention
    Nissim, I
    Horyn, O
    Nissim, I
    Daikhin, Y
    Luhovyy, B
    Yudkoff, M
    FASEB JOURNAL, 2006, 20 (05): : A893 - A893
  • [44] IFOSFAMIDE - INDUCED ENCEPHALOPATHY
    SEDDIGH, S
    DILLMANN, U
    KRYSINSKI, N
    KRAMER, G
    AKTUELLE NEUROLOGIE, 1993, 20 (06) : 214 - 215
  • [45] Ifosfamide-induced encephalopathy: symptoms and efficacy of methylene blue (MB) in the treatment and prevention of this adverse effect
    Barthelemi, L.
    Bara, E.
    Descoeur, J.
    Hillaire-Buys, D.
    Mathieu, O.
    Sirvent, N.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2015, 29 : 24 - 24
  • [46] Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy: report of 12 cases and a review of the literature
    J Pelgrims
    F De Vos
    J Van den Brande
    D Schrijvers
    A Prové
    J B Vermorken
    British Journal of Cancer, 2000, 82 : 291 - 294
  • [47] INFLUENCE OF BUTHIONINE SULFOXIMINE ON THE LETHALITY OF IFOSFAMIDE AND IFOSFAMIDE-INDUCED UROTOXICITY IN MICE
    ISHIKAWA, M
    TAKAYANAGI, Y
    SASAKI, K
    RESEARCH COMMUNICATIONS IN CHEMICAL PATHOLOGY AND PHARMACOLOGY, 1989, 63 (03): : 455 - 458
  • [48] Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy:: report of 12 cases and a review of the literature
    Pelgrims, J
    De Vos, F
    Van den Brande, J
    Schrijvers, D
    Prové, A
    Vermorken, JB
    BRITISH JOURNAL OF CANCER, 2000, 82 (02) : 291 - 294
  • [49] Encephalopathy after High-Dose Ifosfamide A Retrospective Cohort Study and Review of the Literature
    Sweiss, Karen I.
    Beri, Rakesh
    Shord, Stacy S.
    DRUG SAFETY, 2008, 31 (11) : 989 - 996
  • [50] N-acetylcysteine as a Novel Prophylactic Treatment for Ifosfamide-Induced Nephrotoxicity in Children: Translational Pharmacokinetics
    Hanly, Lauren N.
    Chen, Nancy
    Aleksa, Katarina
    Cutler, Murray
    Bajcetic, Milica
    Palassery, Rasmi
    Regueira, Osvaldo
    Turner, Curtis
    Baw, Bandar
    Malkin, Becky
    Freeman, David
    Rieder, Michael J.
    Vasylyeva, Tetyana L.
    Koren, Gideon
    JOURNAL OF CLINICAL PHARMACOLOGY, 2012, 52 (01): : 55 - 64